TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2906946
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo exposure to aspirin and placebo capsules
Study: 2764865
Drug: Generalization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generalization of treatment effects
Study: 19229804
Drug: Mechanical compression
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical compression therapy followed by a compression bandage (302 patients, group 1)
Study: 11753130
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management (phytotherapy, alpha‐blockers, 5 alpha‐reductase inhibitors)
Study: 10091954
Drug: Acamprosate 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 2 g daily for 7 days
Study: 2127674
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nicergoline
Study: 2127674
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nicergoline
Study: 2086492
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg co-dergocrine mesylate (CDM)
Study: 37863
Drug: Flunitrazepam 1
Normalized name: flunitrazepam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 1 mg i.v.
Study: 37863
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg i.v.
Study: 30290018
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.33% gel once a day for 4 days
Study: 14602740
Drug: Troglitazone (TGZ)
DrugBank: Troglitazone (DB00197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Troglitazone (TGZ) 150 mg/d
Study: 14602740
Drug: Troglitazone (TGZ)
DrugBank: Troglitazone (DB00197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Troglitazone (TGZ) 300 mg/d
Study: 14602740
Drug: Troglitazone (TGZ)
DrugBank: Troglitazone (DB00197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Troglitazone (TGZ) 600 mg/d
Study: 1860284
Drug: Metronidazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (3 times daily for 7 days)
Study: 1860284
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times daily for 7 days)
Study: 6802408
Drug: Verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (120 mg single oral dose)
Study: 29394491
Drug: l-citrulline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-citrulline (6 g/day)
Study: 24969056
Drug: Rifaximin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (200 mg, 2 tablets bid, for 7 days monthly for 12 months) and probiotic VSL#3 (450 × 10(9) FU per day)
Study: 12856483
Drug: Increased digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased digoxin synthesis, decreased membrane Na(+)‐K+ ATPase activity, increased tryptophan catabolites (serotonin, quinolinic acid, and nicotine), decreased tyrosine catabolites (dopamine, noradrenaline, and morphine) in creative individuals; correlated with right hemispheric dominance.
Study: 12856483
Drug: Decreased digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decreased digoxin synthesis, increased membrane Na(+)‐K+ ATPase activity, decreased tryptophan catabolites (serotonin, quinolinic acid, and nicotine), increased tyrosine catabolites (dopamine, noradrenaline, and morphine) in non-creative individuals; correlated with left hemispheric dominance.
Study: 8988452
Drug: Trazodone 100
Normalized name: traZODone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 100 mg/day + Pindolol 7.5 mg/day
Study: 9315986
Drug: Trazodone 100
Normalized name: traZODone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 100 mg/day + Fluoxetine 20 mg/day
Study: 8988452
Drug: Trazodone 100
Normalized name: traZODone 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 100 mg/day + Placebo
Study: 6439565
Drug: Intranasal disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal disodium chromoglycate
Study: 29156378
Drug: Robotic-assisted gait
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted gait training therapy using Lokomat®Pediatric, 20 sessions
Study: 18561722
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day purified omega-3 fatty acids
Study: 11803070
Drug: 0.5ml (15.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml (15.5 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Study: 11803070
Drug: 0.25ml (7.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25ml (7.75 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Study: 10357750
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vitamin E
Study: 10357750
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin E
Study: 3127028
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (Premarin, 1.25 mg/day)
Study: 30610781
Drug: Sequential paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential paclitaxel followed by gemcitabine (4 cycles each)
Study: 28515196
Drug: Therapist-guided internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT) for 12 weeks
Study: 28515196
Drug: Therapist-guided internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT)
Study: 29574635
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 25 (LM25)
Study: 22763161
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin glargine (GL)
Study: 19717480
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P(ET,CO(2)) >or=36 mmHg with Wells score <4
Study: 12204666
Drug: Total radiation
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total radiation dose of 44.7 Gy with a standard deviation of 4.6 Gy
Study: 11379854
Drug: 1% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% amino acid‐based PD solution buffered with bicarbonate (Amino/Bic)
Study: 11379854
Drug: 1.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glucose anhydrous‐containing bicarbonate‐buffered solution (Glu/Bic)
Study: 11379854
Drug: 1.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glucose anhydrous‐based dialysis solution with lactate (Glu/Lac)
Study: 6489417
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 2.5 g
Study: 6489417
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 10 g
Study: 6489417
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 25 g
Study: 2872336
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 50 g
Study: 6489417
Drug: Water 300
Normalized name: clindamycin phosphate/dextrose 5 % in water 300 mg/50 mL INTRAVEN IV SOLUTION, PIGGYBACK, BOTTLE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water 300 ml only
Study: 29552921
Drug: Manual restraint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual restraint (intermittent holding restraint during therapy)
Study: 22244160
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus intravenous bevacizumab (10 mg/kg IV every 14 days)
Study: 12243438
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.25 x 10(6) KIU aprotinin (4 doses)
Study: 9951268
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of midazolam (mdz) using a nasal route
Study: 9951268
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of diazepam (dz) per os 45' before induction
Study: 2340945
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg furosemide
Study: 2661389
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide
Study: 2015169
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg flosequinan
Study: 2015169
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg flosequinan
Study: 6948488
Drug: Intra-articular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injections of a mixture of corticosteroid and local anaesthetic, given once a week for three weeks.
Study: 6948488
Drug: Occlusal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal treatment including splints, grinding on natural teeth, and occlusal correction of complete dentures.
Study: 25381096
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with preventive swallowing rehabilitation
Study: 16000605
Drug: Cisplatin-based adjuvant
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based adjuvant chemotherapy
Study: 19597387
Drug: Individualized adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized adjuvant chemotherapy (discussed conceptually)
Study: 9579121
Drug: Full angioscopic
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full angioscopic preparation
Study: 9054083
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation
Study: 7647691
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.4 g n-3 fatty acids/day)
Study: 7647691
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil supplements
Study: 791332
Drug: Labetalol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (400 mg daily)
Study: 31301920
Drug: Zoster vaccine
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoster vaccine live (ZVL)
Study: 31441836
Drug: TXA +
Normalized name: Tranexamic acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA + Dexa (10 mg Dexa just after anesthesia and repeated at 24 hours post-surgery)
Study: 19338427
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg (third injection)
Study: 15515413
Drug: Local injections
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injections of tropisetron
Study: 15515413
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of local anaesthetics combined with depot corticosteroids
Study: 15515413
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of prilocaine
Study: 3624684
Drug: Aerosolized atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized atropine (1.5 mg)
Study: 3624684
Drug: Aerosolized lidocaine
Normalized name: Lidocaine Topical Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized lidocaine (80 to 160 mg)
Study: 3624684
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (50 mg three times daily for 10 doses)
Study: 27849355
Drug: Acute cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute cocoa flavanol (903 mg)
Study: 20394488
Drug: High-quality skin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-quality skin cream
Study: 20394488
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream vehicle
Study: 20394488
Drug: Cold cream
Normalized name: cold cream
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold cream emulsion
Study: 18028577
Drug: Opioid-free continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free continuous psoas compartment block with 0.75% ropivacaine (0.4 mL kg(‐1) loading dose followed by 10 mL h(‐1) of 0.2% ropivacaine for 48 hours)
Study: 18028577
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.1% morphine and 0.12% ketorolac at 2 mL h(‐1) for 48 hours
Study: 16210049
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (desloratadine 5 mg + montelukast 10 mg)
Study: 12371974
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment after biopsy
Study: 9925057
Drug: RIF with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIF with aluminum‐magnesium antacid
Study: 1958387
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen (TAM) treatment
Study: 7579503
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic adjuvant therapy (Control)
Study: 27072796
Drug: Psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic treatment recommendation
Study: 27072796
Drug: Psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic treatment recommendation in psychiatric university hospital
Study: 27072796
Drug: Psychotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapeutic treatment recommendation for patients with F2 diagnosis
Study: 17158523
Drug: Combined antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antithrombotic therapy (antiplatelet plus moderate-level anticoagulant)
Study: 8958162
Drug: L-Arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (1 g, two daily dosages)
Study: 8958162
Drug: L-Arginine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Arginine (after crossover)
Study: 20138778
Drug: Daily respiratory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily respiratory physiotherapy interventions until discharge
Study: 15123946
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection for pain relief
Study: 26630719
Drug: Ketoprofen 12.5
Normalized name: ketoprofen 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 12.5 mg
Study: 14980334
Drug: Droperidol 2.5
Normalized name: droperidol 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 2.5 mg i.v.
Study: 29466249
Drug: TPP-related compounds
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPP-related compounds (specifically bis-TPP, 2-butene-1,4-bis-TPP)
Study: 29466249
Drug: TPP-related compounds
Normalized name: Latanoprost related compound e
DrugBank: Latanoprost acid (DB19360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPP-related compounds (general)
Study: 28803715
Drug: 20μg Hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20μg Hepatitis E Virus (HEV) p179 vaccine
Study: 28803715
Drug: 30μg HEV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30μg HEV vaccine p239 Hecolin (control)
Study: 28803715
Drug: 40μg Hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40μg Hepatitis E Virus (HEV) p179 vaccine
Study: 25680558
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of trabectedin treatment after six cycles (27 patients)
Study: 25680558
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of trabectedin treatment after six cycles (26 patients)
Study: 25680558
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of trabectedin treatment (27 patients)
Study: 25680558
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of trabectedin treatment (26 patients)
Study: 23053269
Drug: Bosutinib 200
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 200 mg (single oral dose)
Study: 18841294
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of Bivalirudin
Study: 12500072
Drug: Blinded rater's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded rater's guess of treatment assignment
Study: 10623703
Drug: Docetaxel at
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at a dose of 100 mg/m(2) intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days
Study: 9181181
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg NET-90
Study: 9181181
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg NET-90
Study: 8251354
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cetirizine (10 mg at night) and ranitidine (150 mg twice daily)
Study: 8251354
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terfenadine (120 mg twice daily) and ranitidine (150 mg twice daily)
Study: 8251354
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg at night)
Study: 8251354
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg twice daily)
Study: 25792492
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once weekly
Study: 12769445
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran intervention (60 g oat bran daily, corresponding to 20 g dietary fiber)
Study: 7831429
Drug: Yohimbine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (0.4 mg/kg)
Study: 3928015
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg vitamin K1 per week
Study: 3928015
Drug: 20.15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.15 mg vitamin K1 per week
Study: 3928015
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vitamin K1 per day
Study: 19185249
Drug: Capsules of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of nondiabetic patients without trypan blue
Study: 19185249
Drug: Capsules of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of diabetic patients without trypan blue
Study: 15185837
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help treatment (GSH)
Study: 15185837
Drug: Minimal guided
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal guided self-help treatment (M-GSH)
Study: 1551787
Drug: Fluoxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (8 weeks treatment)
Study: 25149384
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 weeks treatment)
Study: 3925744
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN), 40 to 120 mg/day
Study: 3925744
Drug: Nifedipine, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 40 to 120 mg/day
Study: 3925744
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of ISDN and calcium antagonist
Study: 20582970
Drug: LSA2L2-type maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LSA2L2-type maintenance therapy
Study: 14585938
Drug: Ximelagatran 36
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 36 mg twice daily
Study: 1312854
Drug: Lisinopril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-40 mg twice daily)
Study: 2405556
Drug: Nifedipine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20-40 mg twice daily)
Study: 24494280
Drug: Acupuncture rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture rehabilitation group (acupuncture at specific points plus comprehensive rehabilitation therapy)
Study: 24494280
Drug: Simple rehabilitation
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple rehabilitation group (comprehensive rehabilitation therapy only)
Study: 21563716
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group interventions (visual assessment, education, bed/pillow dust mite encasings, treatment of lead‐based paint hazards)